Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society

Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are currently conducted only in research settings. Yet, US Food and Drug Administration approval of a disease‐modifying treatment for symptomatic individuals, improved understanding of the “preclinical” phase of...

Descripción completa

Detalles Bibliográficos
Autores principales: Erickson, Claire M., Clark, Lindsay R., Ketchum, Fred B., Chin, Nathaniel A., Gleason, Carey E., Largent, Emily A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405485/
https://www.ncbi.nlm.nih.gov/pubmed/36035626
http://dx.doi.org/10.1002/dad2.12339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405485/
https://www.ncbi.nlm.nih.gov/pubmed/36035626
http://dx.doi.org/10.1002/dad2.12339

Ejemplares similares